"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 5 | 0 | 5 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 6 | 10 |
| 2003 | 3 | 2 | 5 |
| 2004 | 6 | 1 | 7 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 0 | 4 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 1 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 4 | 2 | 6 |
| 2012 | 4 | 5 | 9 |
| 2013 | 6 | 1 | 7 |
| 2014 | 4 | 4 | 8 |
| 2015 | 13 | 4 | 17 |
| 2016 | 6 | 0 | 6 |
| 2017 | 6 | 2 | 8 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 3 | 7 |
| 2020 | 6 | 5 | 11 |
| 2021 | 5 | 2 | 7 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Cohen S, Cowan V, Rohan V, Pavlakis M, Curry MP, Adler JT, Safa K, Fleishman A, Shenkel J, Rodrigue JR. Willingness of Kidney and Liver Transplant Candidates to Receive HCV-Infected Organs. J Surg Res. 2022 Oct; 278:342-349.
-
Behnke C, Nissim O, Simerlein W, Beeker K, Tarleton JL, Lazenby GB. Quality improvement to evaluate and provide treatment for chronic hepatitis C postpartum. J Am Pharm Assoc (2003). 2022 May-Jun; 62(3):864-869.
-
Hanna GS, Choo YM, Harbit R, Paeth H, Wilde S, Mackle J, Verga JU, Wolf BJ, Thomas OP, Croot P, Cray J, Thomas C, Li LZ, Hardiman G, Hu JF, Wang X, Patel D, Schinazi RF, O'Keefe BR, Hamann MT. Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. J Nat Prod. 2021 11 26; 84(11):3001-3007.
-
Ball LE, Agana B, Comte-Walters S, Rockey DC, Masur H, Kottilil S, Meissner EG. Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. J Viral Hepat. 2021 11; 28(11):1614-1623.
-
Brennan PG, Wright K, Miles MVP, Lintner AC, Alexander KM, Kahn SA. Delineating the Role of Serum Immunoglobulin Titers in Burn Patients at High Risk for Herpes Simplex Virus Infection. J Burn Care Res. 2021 08 04; 42(4):646-650.
-
Novotny LA, Evans JG, Su L, Guo H, Meissner EG. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses. 2021 06 09; 13(6).
-
Eckard AR, Borow KM, Mack EH, Burke E, Atz AM. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021 05; 147(5).
-
Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021 04; 160(5):1502-1520.e1.
-
Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjug Chem. 2021 01 20; 32(1):215-223.
-
Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.